Clinically Amyopathic Dermatomyositis Complicated by Rapidly Progressive Interstitial Lung Disease

Yoshio Hisata, MD; Eisuke Sasaki, MD, PhD; Yosuke Harada, MD, PhD; Hirofumi Nakano, MD, PhD; Shinji Naito, MD, PhD; Takashi Sugioka, MD, PhD

doi:10.60227/jhgmeibun.2.3_85

Case report

Clinically Amyopathic Dermatomyositis Complicated by Rapidly Progressive Interstitial Lung Disease

Yoshio Hisata, MD, Eisuke Sasaki, MD, PhD, Yosuke Harada, MD, PhD, Hirofumi Nakano, MD, PhD, Shinji Naito, MD, PhD, Takashi Sugioka, MD, PhD

Author information

Keywords: clinically amyopathic dermatomyositis, anti-melanoma differentiation-associated gene 5 antibody, rapidly progressive interstitial lung disease

JOURNAL FREE ACCESS

2020 Volume 2 Issue 3 Pages 85-89

DOI https://doi.org/10.60227/jhgmeibun.2.3_85

Details

Abstract

Clinically amyopathic dermatomyositis (CADM) may be complicated by rapidly progres- sive interstitial lung disease (RP-ILD) and consequently has a poor prognosis. Anti-melanoma differentiation-associated gene 5 (anti-MDA5) antibody is reportedly associated with RP-ILD in patients with CADM and is useful for early diagnosis. The characteristic skin rash of CADM can be a clue to early diagnosis. In patients with such a rash, we should consider measuring the anti- MDA5 antibody level and perform magnetic resonance imaging of the skeletal muscle, even without clinical or laboratory findings of myopathy.

Corresponding author

Register with J-STAGE for free!